These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34806915)

  • 1. Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity.
    Xu Z; Lin X
    Stat Methods Med Res; 2022 Mar; 31(3):534-548. PubMed ID: 34806915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
    Zhou H; Chen C; Sun L; Zeng Z
    Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
    Guo W; Wang SJ; Yang S; Lynn H; Ji Y
    Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
    Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
    Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
    Shi H; Cao J; Yuan Y; Lin R
    Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. qTPI: A quasi-toxicity probability interval design for phase I trials with multiple-grade toxicities.
    Ling H; Shi H; Yuan N; Ji Y; Lin X
    Stat Methods Med Res; 2023 Jul; 32(7):1389-1402. PubMed ID: 37278183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology.
    Lin X; Ji Y
    Stat Methods Med Res; 2021 Mar; 30(3):843-856. PubMed ID: 33327870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The i3+3 design for phase I clinical trials.
    Liu M; Wang SJ; Ji Y
    J Biopharm Stat; 2020 Mar; 30(2):294-304. PubMed ID: 31304864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Logistic retainment interval dose exploration design for Phase I clinical trials of cytotoxic agents.
    Murray TA
    Pharm Stat; 2021 Jul; 20(4):850-863. PubMed ID: 33738967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.
    Lin R; Yuan Y
    Biostatistics; 2020 Oct; 21(4):807-824. PubMed ID: 30984972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
    Takeda K; Yamaguchi Y; Taguri M; Morita S
    Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials.
    Yin J; Yuan Y
    J Biopharm Stat; 2020 Nov; 30(6):1006-1025. PubMed ID: 32966167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs.
    Chiuzan C; Garrett-Mayer E; Yeatts SD
    Clin Trials; 2015 Feb; 12(1):24-33. PubMed ID: 25349178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.